Optimal Timing of Physical Activity in Cancer Treatment (ACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01642680|
Recruitment Status : Completed
First Posted : July 17, 2012
Last Update Posted : August 11, 2021
|Condition or disease||Intervention/treatment||Phase|
|Metabolic Syndrome Vascular Disorders Cardiovascular Risk Factors Fatigue||Other: A tailored physical activity program during chemotherapy Other: A tailored physical activity program after chemotherapy||Not Applicable|
Improved treatment is partly responsible for the increased survival and life expectancy in cancer patients. However, such treatment can be harmful as well, and cancer survivors therefore, face an increased risk of second malignancies and other chronic diseases, e.g. cardiovascular diseases and metabolic syndrome.
Due to the growing number of cancer patients and survivors, attention for rehabilitation, especially physical training, is growing. Several meta-analyses show the beneficial effects of physical training on several outcomes such as physical fitness, muscle strength, fatigue and quality of life, and a few studies showed the effect of exercise on physical active behaviour. However, studies on the effect of timing of exercise are lacking.
The present study aims to insert a tailored physical activity program early versus late in the chemotherapy based cancer treatment and will yield data about its safety and efficacy. We hypothesize that a tailored physical activity program during early cancer treatment may more be effective to reduce long-term cancer treatment toxicities and morbidity in cancer survivors compared to a program after cancer treatment.
Primary Objective: To investigate whether a tailored physical activity program that starts during chemotherapy (early) is superior in terms of physical fitness, as determined by VO2 peak at one year, to a program that starts after completion of chemotherapy (late).
Secondary Objectives: To examine the effect of the physical activity program on muscle strength and activity level, change in metabolic and cardiovascular damage parameters, cardiovascular risk factors and quality of life including self-efficacy, motivation for exercise, and fatigue.
Design: This protocol describes a multicenter, randomized study with 2 arms. Patients who will be treated with curative systemic chemotherapeutic treatment for testicular cancer, early colon cancer, early breast cancer or B-NHL will be randomized into an early or late PA program group. The early group will start the PA program during chemotherapy (for 12 weeks) until 12 weeks after completion of chemotherapy (total 24 weeks of training). The late group will start the same program (total of 12 weeks) after completion of chemotherapy. The longitudinal effects of the physical activity (PA) program for all participants will be evaluated at different time points in the UMCG: before start of chemotherapeutic treatment; at the start of the PA program and at 3, 6, 18 months after starting the PA program and 18 months after the last chemotherapy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||266 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Optimal Timing of a Tailored Physical Activity Program During Chemotherapeutic Cancer Treatment to Reduce Long-term Cardiovascular Morbidity|
|Actual Study Start Date :||January 24, 2013|
|Actual Primary Completion Date :||October 22, 2020|
|Actual Study Completion Date :||October 22, 2020|
Experimental: Physical activity during chemotherapy
This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
Other: A tailored physical activity program during chemotherapy
The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
Active Comparator: Physical activity after chemotherapy
This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
Other: A tailored physical activity program after chemotherapy
The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
- Difference in VO2 peak between the groups after completion of the PA program, measured by cardiopulmonary exercise testing (CPET). [ Time Frame: 1,5 year ]
The aim of this study is investigate whether a tailored PA program that starts early (during curative chemotherapy with cardiovascular toxic potential) is superior in terms of reducing long-term cancer-treatment-related metabolic syndrome and cardiovascular morbidity to a program that starts late (after completion of chemotherapy).
The VO2 at the peak of the exercise will be defined as peak oxygen uptake (VO2 peak), measured by cardiopulmonary exercise testing (CPET) on a stationary bicycle ergometer. The CPET is considered to be the most precise measure of cardio-respiratory fitness and is recommended for use in order to determine a patient's objective or subjective difference in exercise capacity
- Muscle strength using a hand-held dynamometer [ Time Frame: 1,5 year ]Maximal voluntary isometric muscle force of the right and left extremity of extension of the knee, flexion of the knee, flexion of the elbow and extension of the elbow will be measured using a hand-held dynamometer. The "break method" will be used for all measurements. To employ this technique, the examiner gradually overcomes the force exerted by the patient until the extremity gives way. All measurements will be performed at least three times, with recovery intervals of at least 10 seconds. The peak forces (in Newtons) will be recorded and mean values of three technically correct measurements will be taken for analysis.
- Intima media thickness will be measured with vascular ultrasound [ Time Frame: 1,5 year ]Vascular damage will be determined with the intima-media thickness (IMT) of the common carotid artery and femoral artery, performed with an Ultrasound technique.
- Cholesterol levels, measured in blood [ Time Frame: 1,5 year ]Measured in blood, in mmol/L
- Triglyceride levels, measured in blood [ Time Frame: 1,5 year ]Measured in blood, in mmol/L
- Glucose levels, measured in blood [ Time Frame: 1,5 year ]Measured in blood, in mmol/L
- Body mass index, calculated with formula (see below) [ Time Frame: 1,5 year ]BMI (body mass index): weight in kilograms divided by height in meters squared
- Health related quality of life measured with the EORTC QLQ-C30 [ Time Frame: 1,5 year ]Quality of life will be measured with the European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire Core 30 (QLQ-C30) version 3.0 questionnaire
- Patient reported self-efficacy measured using the ALCOS instrument [ Time Frame: 1 year ]Patient reported general self-efficacy, measuring the patients' expectations of their general capacities, will be evaluated using the Dutch version of the General Self-Efficacy Scale (GSES), the "Algemene Competentie Schaal" (ALCOS)
- Patient reported fatigue measured with the Multi-dimensional Fatigue Inventory [ Time Frame: 1,5 year ]The Multi-dimensional Fatigue Inventory is a validated 20-item questionnaire on different domains of fatigue
- Patient reported physical activity level with the PASE questionnaire [ Time Frame: 1,5 year ]Physical activity will be assessed with the Sum score of the Physical Activity Scale for the Elderly questionnaire (PASE). This questionnaire consists of questions on leisure time, household and work-related activities.
- DNA collection [ Time Frame: 1,5 year ]Whole blood will be drawn of patients and collected in EDTA tubes. DNA isolations and the Global Screening Array will be performed at the Human Genomics Facility (HuGeF) of the Genetic Laboratory of the Department of Internal Medicine at Erasmus MC, Rotterdam, the Netherlands
- Diffusion capacity of the lungs [ Time Frame: 1,5 year ]Corrected for hemoglobin.
- Forced vital capacity (FVC) will be assessed by use of dynamic spirometry [ Time Frame: 1,5 year ]Measured by means of dynamic spirometry
- Forced expiratory volume in one second (FEV1) will be assessed by use of dynamic spirometry, [ Time Frame: 1,5 year ]Measured by means of dynamic spirometry
- FEV1/FVC ratio will be assessed by use of dynamic spirometry, [ Time Frame: 1,5 year ]Measured by means of dynamic spirometry
- Senescence with markers of the senescence- associated secretory phenotype [ Time Frame: 1,5 year ]
Senescence will be measured in a subset of testicular cancer patients.
Markers of scenescence will be obtained from a skin biopsy and fat biopsy. Also, additional blood samples will be assessed to establish markers of the senescence- associated secretory phenotype.
- Cardiac function with echocardiography (Ultrasound technique) [ Time Frame: 1,5 year ]Cardiac function will be measured at baseline and at the final measurement (e.g. left ventricular ejection fraction)
- Body composition will be assessed with a DEXA scan [ Time Frame: 1,5 year ]With the DEXA scan, measurements of body composition will be obtained.
- PAI-antigen, measured in blood serum [ Time Frame: 1,5 year ]Endothelial activation will be determined with PAI antigen in blood serum, in ug/L
- t-PA, measured in blood serum [ Time Frame: 1,5 year ]Endothelial activation will be determined with t-PA antigen in blood serum, in ug/L
- Factor VIII, measured in blood serum [ Time Frame: 1,5 year ]Endothelial activation will be determined with factor VIII in blood serum, in %
- Von Willebrand factor, measured in blood serum [ Time Frame: 1,5 year ]Endothelial activation will be determined with von Willebrand facor in blood serum, in %
- Fibrinogen, measured in blood serum [ Time Frame: 1,5 year ]Endothelial activation will be determined with fibrinogen in blood serum, in g/L
- Advanced glycation end products (AGEs) will be determined by measuring skin auto fluorescence. [ Time Frame: 1,5 year ]Advanced glycation end products will be measured with an AGEreader
- Blood pressure, measured with a blood pressure cuff [ Time Frame: 1,5 years ]Systolic and diastolic blood pressure in mmHg
- Fat percentage with skinfold measurement [ Time Frame: 1.5 years ]Skinfold measurement of biceps, triceps, sub scapula and supra iliaca
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642680
|University Medical Centre Groningen|
|Groningen, Netherlands, 9713GZ|
|Principal Investigator:||Annemiek Walenkamp, PhD||University Medical Center Groningen|